Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...

Pfizer is making strides in the rapidly growing weight management market. The company is committed to developing a franchise around obesity and cachexia treatments. This focus aligns with the ...

On behalf of the Pfizer team, thank you for joining us ... by the potential for a breakthrough for patients with cancer ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

Related MS might increase risk of certain cancers Colonoscopies among young people on the rise Pfizer: Potential cachexia cancer drug shows life-saving promise About 11 weeks after the injection ...

Pfizer is making strides in the rapidly growing weight management market. The company is committed to developing a franchise around obesity and cachexia treatments. This focus aligns with the ...